SimianX AI LogoSimianX AI

Asset profile

lecanemab-irmb · Biogen (BIIB)

Indication
early Alzheimer’s disease (mild cognitive impairment or mild dementia due to Alzheimer’s disease)
Also known as
LEQEMBI IQLIK, lecanemab subcutaneous injection, LEQEMBI
CompanyBIIBBiogen

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates si…

Start live analysis of BIIBRun 8-agent AI analysis

On the calendar

Nothing scheduled in this window.

Timeline

Newest first.

More from Biogen

Other drugs and candidates from the same company tracked in this sector.

dapirolizumab pegolsystemic lupus erythematosusdiranersenearly Alzheimer's diseaselitifilimabsystemic lupus erythematosus (SLE)salanersenspinal muscular atrophyzorevunersenDravet syndrome
lecanemab-irmb · Biogen (BIIB) — FDA Timeline & Readiness Checklist | SimianX AI